Navigation Links
Stem cell therapies for heart disease -- 1 step closer
Date:10/30/2008

New research from the University of Bristol brings stem cell therapies for heart disease one step closer. The findings reveal that our bodies' ability to respond to an internal 'mayday' signal may hold the key to success for long-awaited regenerative medicine.

Dr Nicolle Krnkel and colleagues at the Bristol Heart Institute have discovered how our bodies initiate DIY rescue and repair mechanisms when blood supply is inadequate, for example in diabetic limbs or in the heart muscle during heart attack. Their findings also provide a practical step to advance progress in stem cell therapies.

In healthy people, reduced oxygen supply can occur in certain situations, e.g. after an injury. The affected tissues release chemical messengers that 'call' to a type of circulating stem cells (EPCs) for help to re-establish blood supply via the growth of new blood vessels. A group of Bristol researchers have found that kinins, for long time considered inflammatory substances, are among the messengers supporting blood vessel growth.

In this study, published in Circulation Research, Dr Krnkel and colleagues found that EPCs respond to kinins by travelling to the target tissue and invading it to assist healing. In patients with angina, EPCs cannot respond to the distress call because they lack a kinin sensor (the 'kinin receptor') on their surface. The oxygen-starved tissue is therefore left with reduced blood supply.

In heart attack patients they saw that a proportion of the circulating EPCs were able to sense the kinin signal and respond.

Dr Krnkel, Research Associate at the Bristol Heart Institute, said: "Our findings showed that heart attack patients possess the functional cells needed to repair blood supply to their heart, but they're hidden amongst a muddle of others."

The team purified the kinin-sensitive EPCs from the total stem cell population to create an enriched sample that has huge potential as a powerful re
'/>"/>

Contact: Joanne Fryer
joanne.fryer@bristol.ac.uk
44-011-733-17276
University of Bristol
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Texcel Introduces Innovative Programmable, Implantable Stimulation System for R&D of Specialty Stimulation Therapies
2. Study shows steroid therapies following transplant can be eliminated
3. Study Evaluates Laser Therapies for Hair Removal
4. New Journal to Explore Neurodegenerative, Neuroprotective and Euroregenerative Therapies!
5. New way to control protein activity could lead to cancer therapies
6. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
7. Study Lets Teens Sound Off on Acne Therapies
8. Sales of Emerging Novel Pain Therapies Will Represent More than One-Fifth of the Total Pain Drug Market by 2023
9. UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies
10. 1st World Congress On Interventional Therapies for Type 2 Diabetes
11. Insight into mechanisms of diabetes-induced microvascular disease reveals new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Widely regarded as ... genital plastic surgery and women’s sexual health, Dr. Goodman ... Board of http://www.labiaplastysurgeon.com , the nationally ranked ... proud to be a member of this informative and ... the appointment. “I’ve already worked with the President ...
(Date:5/20/2013)... May 20, 2013 AURORA, Colo. – ... online accredited university, has developed a Bachelor of ... assess how they feel about continuing their education and ... print out the complimentary worksheet, respond to ten statements ... they rate on a BSN-readiness scale. , New industry ...
(Date:5/20/2013)... Columbus, OH (PRWEB) May 20, 2013 ... an experienced medical device law firm, report that two ... the coming months in state and federal litigations established ... On June 11th, the first C.R. Bard bellwether trial ... Court, Southern District of West Virginia. (In re: ...
(Date:5/20/2013)... Durham, N.C. (PRWEB) May 20, 2013 ... Training Institute (IFPTI), will speak at North Carolina Food ... Food is Good Business: The Need for Partnerships – ... , The two-day conference, scheduled for May 22-23 at ... role partnerships across the food sector have in protecting ...
(Date:5/19/2013)... Houston,TX (PRWEB) May 20, 2013 Due ... companies with online advertising, MileageAds.com has decided to invite ... advertisements through their ad network. , Businesses in ... of success with online marketing, specifically with ad networks. ... advice, information and legal services and are unsure where ...
Breaking Medicine News(10 mins):Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 2Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 3Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 2Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2
... solutions to tackle obesity, the latest on the Northwick ... sport and the Olympics will be highlighted at ... Pharmacological Society (BPS), Europe,s leading pharmacological research society, is ... attracting experts from across the world. , Running from ...
... Public Relations Worldwide (Ogilvy PR), an integrated global communications ... five-year comprehensive communications support contract with the National Cancer ... will be performed by Ogilvy PR,s Washington, DC-based Social ... consulting subsidiary, Feinstein Kean Healthcare (FKH). , ...
... But American physicians often overlook the illness, delaying diagnosis ... doctors view leprosy as a scourge of Biblical times ... U.S. cases, with more diagnosed each year, experts say. ... remains a largely forgotten illness, U.S. physicians are often ...
... peginterferon in combination with ribavirin for previously untreated children ... , KENILWORTH, N.J., Dec. ... today announced that the U.S. Food and Drug Administration ... and REBETOL(R) (ribavirin, USP) combination therapy for use in ...
... ANN ARBOR, Mich., Dec. 12 Terumo Corporation ... that,they have entered into an agreement to settle ... companies have a number of lawsuits pending,in which ... The litigations all,involve methods and devices used ...
... Dec. 12 Dignitas Personae (The Dignity of ... Doctrine of the Faith (CDF) on ethical issues arising from ... and human procreation in our heavily scientific age, said Cardinal ... of Catholic Bishops. , , ...
Cached Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
The Urology C-Arm Table features motorized actuation of height, X-Y, lateral roll and Trendelenburg motions of the tabletop, and is fully accessorized for urologic procedures....
... UroVantage from HealthTronics is ... most versatile urology table ... leap forward in design ... urologists by urologists, the ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... The Maxxis™ 400 is a bariatric ... safety for individuals in the home care ... 1000 lbs. (or combined weight of 2) ... depending on frame size selected , ...
Medicine Products: